{"id":"semaglutide-empagliflozin","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"5–10","effect":"Urinary tract infection"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL2107830","moleculeType":"Small molecule","molecularWeight":"450.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide activates GLP-1 receptors to enhance insulin secretion, slow gastric emptying, and promote satiety, thereby reducing blood glucose and body weight. Empagliflozin inhibits sodium-glucose cotransporter 2 in the kidney, preventing glucose reabsorption and promoting urinary glucose excretion. Together, these mechanisms provide complementary glycemic control and cardiovascular/renal benefits.","oneSentence":"This combination uses a GLP-1 receptor agonist to reduce appetite and blood sugar while an SGLT2 inhibitor increases urinary glucose excretion to lower blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:19.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06410352","phase":"PHASE4","title":"Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome","status":"RECRUITING","sponsor":"University Medical Center, Kazakhstan","startDate":"2024-03-01","conditions":"Metabolic Syndrome","enrollment":220},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06894784","phase":"PHASE3","title":"A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-04","conditions":"Diabetes Type 1","enrollment":36},{"nctId":"NCT05501483","phase":"NA","title":"Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2023-02-08","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06821919","phase":"","title":"Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-05-13","conditions":"Diabetes Mellitus, Kidney Disease","enrollment":70},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT04639414","phase":"PHASE4","title":"Combined Active Treatment in Type 2 Diabetes with NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Diabetes Center","startDate":"2021-03-26","conditions":"Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)","enrollment":192},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06083675","phase":"PHASE3","title":"Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2024-01-26","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05857085","phase":"PHASE4","title":"Novel Therapeutics and Endothelial Dysfunction in T1DM Patients","status":"COMPLETED","sponsor":"General and Teaching Hospital Celje","startDate":"2021-12-15","conditions":"Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers","enrollment":90},{"nctId":"NCT05444153","phase":"PHASE3","title":"Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2022-10-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02863328","phase":"PHASE3","title":"Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-08-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":822},{"nctId":"NCT04061200","phase":"PHASE4","title":"Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-11-01","conditions":"Type 2 Diabetes With Renal Manifestations","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":199,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Semaglutide (GLP-1RA), Empagliflozin (SGLT-2i)"],"phase":"marketed","status":"active","brandName":"Semaglutide, Empagliflozin","genericName":"Semaglutide, Empagliflozin","companyName":"University Medical Center, Kazakhstan","companyId":"university-medical-center-kazakhstan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a GLP-1 receptor agonist to reduce appetite and blood sugar while an SGLT2 inhibitor increases urinary glucose excretion to lower blood glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}